¹ **Iron metabolism disorders of patients with chronic** ² **paracoccidioidomycosis**

- 3
- 4

- 22 E-mail: anamaria.paniago@ufms.br (AMMP)
- 23

Abstract

 Paracoccidioidomycosis (PCM) is caused by *Paracoccidioides* spp.; during infection, some host mechanisms limit the availability of iron, thereby reducing its reproduction. However, *Paracoccidioides* spp*.* can evade the immune defense and, even under limited iron conditions, use this mineral for growth and dissemination. This study evaluated the iron metabolism of 39 patients who were diagnosed with chronic PCM between 2013 and 2021. The forms of iron before treatment and at the time of clinical cure were evaluated based on the following: serum ferritin levels (storage iron); total iron-binding capacity (TIBC) and transferrin saturation (TSAT) level (transport iron); red blood cell (RBC), hemoglobin (Hb), hematocrit (HCT), and soluble transferrin receptor (sTfR) levels; and sTfR/log ferritin ratio 34 (functional iron). The mean age of the patients was 54.5 years $(\pm 6.7 \text{ years})$. Most patients were men (97.4%), rural workers (92.1%), and smokers (84.6%); most had moderate disease severity (66.7%). Before treatment, the median values of all evaluated parameters were within or just slightly outside the normal range of values. However, it is possible to infer that PCM interferes with functional and storage iron because improvements in these parameters after treatment as well as associations with disease severity were observed. Furthermore, 40 moderate correlations were observed between C-reactive protein and the Hb $(r=0.500;$ 41 p=0.002), RBC (r=-0.461; p=0.005), HCT (r=-0.514; p=0.001), and iron levels (r=-0.491; p=0.002). PCM interferes with iron metabolism by transforming functional iron to storage iron, as revealed by anemia, low iron levels with normal TSAT levels, normal TIBC, normal sTfR levels, normal sTfR/log ferritin ratios, and normal or slightly increased ferritin levels. PCM can lead to anemia of inflammation, which can be differentiated from iron deficiency anemia by a careful investigation of the iron form parameters.

Keywords: anemia of inflammation; iron; iron metabolism; paracoccidioidomycosis;

-
-
-
-

Paracoccidioides spp.

Introduction

 Paracoccidioidomycosis (PCM), which is a systemic mycosis endemic to Latin America, is caused by dimorphic fungi, *Paracoccidioides* spp. Infection occurs through the inhalation of infective conidia that are present in the soil; these conidia settle in the lungs and can spread to the lymphatic and hematogenous pathways and other organs. Brazil is the main endemic area for PCM, which is considered the eighth leading cause of mortality associated with chronic infectious diseases in the country [1]. Chronic or adult PCM, which is observed in those older than age 30 years, is the most frequent form of this disease, and it predominantly affects the lungs and mucous membranes of the upper digestive tract and airways [2].

 Similar to other fungal diseases, certain factors are determinants of PCM, such as the inoculum size, pathogenicity, fungus virulence, defense system integrity, and genetic factors [3]. The host organism uses strategies or barriers that prevent fungal diseases, such as inhibiting vital fungal functions by blocking iron uptake; this is because iron is an essential mineral for the proliferation of many pathogens, including *Paracoccidioides* spp. [4] .

 Iron is an essential component of hemoglobin (Hb), myoglobin, and several enzymes, and it has a fundamental role in oxygen transport and electron transfer. Additionally, it acts as a cofactor in many enzymatic processes, including DNA synthesis [5-7] .

 Maintaining control of iron homeostasis is essential in host-pathogen interactions because both compete for this micronutrient. During infection, some host immune mechanisms limit the availability of iron to invading microorganisms, thereby reducing their proliferation [8]. However, many microorganisms, such as *Paracoccidioides* spp., can evade the immune defense; even under limited iron conditions, they can use this mineral for growth

 and dissemination [9]. Therefore, alterations in hematological parameters and iron metabolism can be observed during PCM infection [10].

 In the human body, iron is distributed in different interconnected forms to enable homeostasis. These forms of iron (storage iron, transport iron, and functional iron) can be evaluated separately using laboratory tests, many of which are available and accessible during routine laboratory testing. These tests can assess any disturbances in iron metabolism 83 and the affected iron form [11]. Generally, when there is an iron deficit, these forms are sequentially affected. First, there is a decrease in the storage iron levels, followed by a 85 deficiency in the transport iron level and a reduction in the functional iron level [12,13].

 The host-parasite interaction and consequent inflammatory response lead to changes in iron metabolism dynamics. These changes can be observed in some patients with PCM 88 [14], which is a chronic systemic inflammatory disease requiring long-term treatment. Understanding the frequency and intensity of iron metabolism disturbances in patients with chronic PCM will help improve therapeutic management. Therefore, we analyzed the iron metabolism and different iron forms of patients with chronic PCM before treatment and at the time of clinical cure.

Materials and Methods

Ethical aspects

 This study was approved by the Human Research Ethics Committee of the Federal University of Mato Grosso do Sul (CAAE number 62726016.2.0000.0021). All participants provided written informed consent.

Location, period, and design of the study

- This study was performed between 2013 and 2021 at the outpatient clinic for systemic mycoses of the Infectious and Parasitic Diseases Unit of the University Hospital Maria Aparecida Pedrossian at the Federal University of Mato Grosso do Sul, which is a reference center for infectious diseases, in Campo Grande, Mato Grosso do Sul, Brazil. This analytical study involving prospective data evaluated iron metabolism parameters of patients with chronic PCM before treatment and at the time of clinical cure.
-

Patients

Inclusion and exclusion criteria

 Male and female individuals who were diagnosed with chronic PCM between September 2013 and February 2021 were included. Patients with chronic PCM who died and/or did not undergo laboratory tests at admission, such as serum iron and blood count (hemogram [HMG] test) tests, were excluded, as were patients diagnosed with human immunodeficiency virus, tuberculosis, and/or neoplasia.

Case definition

 Confirmed cases of PCM were those presenting with suggestive clinical manifestations, typical yeast forms of *Paracoccidioides* spp. visualized by mycological, culture, or direct histopathological tests, and/or serum-specific antibodies detected using the double agar gel immunodiffusion test.

Demographic and clinical variables

 Demographic, clinical, and laboratory data were retrieved from a prospective database. They comprised complete routine medical data obtained at the time of diagnosis and during follow-up of the disease. Demographic data, such as sex, age, occupational history, smoking, and clinical disease severity, were collected before treatment.

 Chronic PCM was subdivided into mild, moderate, and severe cases. Mild cases included body mass index (BMI) reduction <5% of the usual BMI and the involvement of one or a few organs without functional changes. Severe cases comprised three or more of the 129 following criteria: BMI reduction $\geq 10\%$ of the usual BMI; severe pulmonary impairment; involvement of other organs, such as the adrenal glands, central nervous system, and bones; enlargement of multiple lymph node chains (superficial or deep chains with pseudotumors [>2.0 cm in diameter] with or without suppuration); and high-titer antibodies. Moderate cases were defined as intermediate cases that were worse than mild cases but not as serious as severe cases [2].

Laboratory analysis

 Blood samples were obtained during the routine medical examination at the time of diagnosis and during follow-up. Laboratory data and complementary laboratory test data were obtained at two stages of routine outpatient follow-up: before treatment and at the time of clinical cure (disappearance of signs and symptoms) [2]. To investigate the iron metabolism of patients with chronic PCM, different forms of iron were evaluated.

Storage iron: Storage iron is iron stored in the body. Serum ferritin levels were analyzed

using an electrochemiluminescence immunoassay (Roche).

 Transport iron: Transport iron is iron that circulates in the body. The total iron-binding capacity (TIBC) was measured using a colorimetric assay (Roche) and the transferrin 146 saturation (TSAT) level, which was calculated as $[TSAT = serum iron/TIBC \times (100)]$; the 147 result was expressed as a percentage $(\%)$. **Functional iron:** Functional iron is related to erythrocyte synthesis and erythropoiesis.

Therefore, to evaluate functional iron, the blood count (HMG test) was evaluated to measure

the Hb level, red blood cell (RBC), level mean corpuscular volume, and mean Hb

concentration (MHC) (XN 3000 series hematology equipment; Sysmex Corporation, Kobe,

Japan). Serum iron was determined using a colorimetric assay (Roche). The soluble

transferrin receptor (sTfR) level was determined using an enzyme-linked immunosorbent

assay (human sTfR ELISA Kit; Elabscience). This test is not routinely performed; therefore,

serum stored in the PCM biobank was used.

The inflammatory process was assessed according to the high-sensitivity serum C-

reactive protein (CRP) level measured using immunoturbidimetry. All analyzed parameters

and values considered normal by the manufacturer are listed in **Table 1**.

9

160 **Table 1. Iron parameters and reference values provided by the manufacturer.**

Statistical analysis

Fig 1. **Flowchart of the selection of participants with chronic paracoccidioidomycosis**

- **(PCM) from 2013 to 2021.**
- HIV, human immunodeficiency virus.
-

12

188 **Table 2. Baseline demographic, clinical, and lifestyle data of 39 patients with chronic**

189 **paracoccidioidomycosis.**

13 Mild 5 (12.8) 4.3 27.4 **Initial treatment** 0.002 Itraconazole 29 (74.4) 57.9 87.0 CMX $10 (25.6)$ 13.0 42.1 190 *Mean. CI, confidence interval; CMX, cotrimoxazole or trimethoprim/sulfamethoxazole; 191 SD, standard deviation. Proportion test: χ^2 goodness of fit. †One-sample t test. 192 193 **Storage iron** 194 Nine (26.5%) patients had increased ferritin levels and two (5.8%) patients had lower 195 than normal ferritin levels before treatment (evaluated before treatment: $n = 34$ patients). An 196 analysis of patients who were evaluated at both time points (before treatment and at the time 197 of clinical cure: $n = 28$ patients) showed that the number of individuals with high ferritin 198 levels decreased $(21.4\%$ before treatment vs. 17.9% at the time of clinical cure; $p = 0.008$). 199 An analysis of the median values showed that those at the time of clinical cure were reduced 200 compared to those before treatment $(p = 0.017)$ (Fig 2). 201 202 203 **Fig 2. Comparison of median serum ferritin values before treatment (BT) and at the** 204 **time of clinical cure (CC) of patients with chronic paracoccidioidomycosis.** 205 Q1, first quartile; Q3, third quartile. Wilcoxon signed rank test. 206 It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.02.10.23285778;](https://doi.org/10.1101/2023.02.10.23285778) this version posted February 14, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has grante

207 **Transport iron**

15

220 **Table 3. Comparison of mean or median values of the transport iron parameters before**

221 **treatment and at the time of clinical cure of 30 patients with chronic**

222 **paracoccidioidomycosis.**

223 Q1, first quartile; Q3, third quartile; SD, standard deviation; TIBC, total iron-binding 224 capacity; TSAT, transferrin saturation. The Wilcoxon signed rank test and paired Student's t 225 test were performed.

226

227 **Functional iron**

 The HMG test was performed to evaluate the Hb, RBC, and HCT levels, mean corpuscular volume, and mean corpuscular Hb level to assess functional iron. Additionally, 230 to complement this evaluation, the serum iron and sTfR values and sTfR/log ferritin ratio were calculated.

232 The HMG test results before treatment $(n = 39)$ showed that 36% $(n = 14)$ of 233 individuals had reduced Hb, RBC, and HCT levels. Anemia was considered when the Hb 234 level was <13.5 g/dL. It was noted that 46.1% ($n = 18$) of patients had anemia; among these 235 patients, 72% (n = 13) had normocytic and normochromic anemia. The mean Hb level among 236 the 18 patients with anemia was 11.2 g/dL (SD, 1.21 g/dL).

17

248 **Table 4**. **Changes in functional iron parameters at the time of clinical cure compared to**

249 **those before treatment of 35 patients with chronic paracoccidioidomycosis.**

*Iron evaluation of 32 patients. The McNemar test was performed. HMG: hemogram; RBCs, red blood cells (total erythrocyte count); HCT, hematocrit.

250

18

252 **Table 5. Comparison of functional iron parameter values before treatment and at the**

253 **time of clinical cure of patients with chronic paracoccidioidomycosis.**

 SD, standard deviation; Q1, first interquartile; Q3, third interquartile; Hb, hemoglobin; RBCs, red blood cells (total erythrocyte count); HCT, hematocrit; MCV, mean corpuscular 256 volume; MCH, mean hemoglobin concentration; sTfR, soluble transferrin receptor; sTfR/log Ferr index, soluble transferrin receptor index/ferritin logarithm. The Wilcoxon signed rank test and paired Student's t test were performed.

Inflammatory process

- with red blood cells (RBCs; total erythrocyte count). (d) CRP with hematocrit (HCT).
- An analysis of the stored iron and functional iron parameters before treatment showed
- a significant difference between values associated with severe and mild/moderate disease
- cases as well as CRP levels (**Table 6**).

21

287 **Table 6. Analysis of iron parameters and CRP levels according to disease severity of**

288 **patients with chronic paracoccidioidomycosis before treatment.**

 Q1, first quartile; Q3, third quartile; TSAT, transferrin saturation; TIBC, total iron-binding 290 capacity; RBC, red blood cells (total erythrocyte count); Hb, hemoglobin; HCT, hematocrit; CRP, C-reactive protein. The Mann-Whitney U test and independent Student's t test were performed.

293

294

²⁹⁵ **Discussion**

296 The acquisition of iron by microorganisms is an important virulence mechanism [16], 297 and it has been reported with *Paracoccidioides* spp. [9, 17]. Additionally, human organisms

 actively control intracellular and systemic iron levels in a way that can contain infection and/or microbial persistence. Therefore, this study compared iron metabolism parameters before treatment and at the time of clinical cure, analyzed them based on PCM severity, and correlated them with the intensity of the inflammatory process in patients with chronic PCM. The demographic and clinical characteristics of the patients corresponded to those reported by other case series studies of chronic PCM that involved mostly male patients who were older than age 40 years, smokers, rural workers, and had moderate PCM [18-22]. Therefore, this sample is representative of the population of PCM patients and allows the generalization of our results.

 The storage iron evaluated during this study had higher median serum ferritin levels before treatment, but they were within the normal range. Although ferritin exists in large amounts in the liver and spleen, only a small amount is detected in the circulation. However, serum quantification is a common and non-invasive method that provides an accurate measurement of storage iron [23]. However, the increase in serum ferritin may be related not only to increased storage iron but also to inflammatory activity. Because serum ferritin is an acute-phase protein in inflammatory and infectious processes and in cancer, the production of apoferritin is increased because of the stimulation of interleukins (ILs) such as IL-1 and IL-6 [24]. Increases in these ILs have been observed in patients with PCM [25].

 During this study, serum ferritin levels were increased in some patients; however, the median values were within the normal range before treatment. At the time of clinical cure, these median values were significantly decreased, suggesting the interference of PCM with this parameter. Additionally, severe cases were associated with higher ferritin levels, probably because of the production of IL-6 caused by fungal infection. A previous study by our group reported similar results [14].

 To assess the transport iron, we evaluated the TIBC, TSAT level, and serum iron/TIBC ratio. Before treatment, the patients in this study had median values that were slightly lower than normal, indicating a non-significant transport iron deficit. Additionally, antifungal therapy did not affect these parameters. A weak negative correlation was observed between the TIBC and CRP level, but no correlation was observed between the TSAT and CRP levels. The TIBC is an indirect measure of circulating transferrin, which can be reduced during inflammatory processes [11]. Therefore, with chronic PCM, the transport iron parameters are less affected than the storage iron and functional iron parameters.

330 A TSAT level <16% is considered indicative of iron deficiency with erythropoiesis; however, the use of this value for this parameter has limitations because both iron levels and the TIBC are lower with inflammatory processes [12, 23]. During our study, TSAT values <16% were found in 8 (20.5%) patients before treatment. However, only one of them had confirmed iron deficiency anemia, which is characterized by low Hb, ferritin, and TSAT levels [26]. A study of the effect of PCM treatment on iron metabolism showed that specific treatment quickly leads to a return to normal values or improvement in iron metabolism, as described with the TIBC, which was lower and normalized soon before antifungal treatment [27].

 In clinical practice, the HMG test results and serum iron level are the first indicators of a change in the iron status. Although our study showed that the parameter values were slightly or not altered before treatment, it was possible to infer that PCM interferes with functional iron because these values improved after treatment and were associated with PCM severity. Additionally, a moderate correlation was observed between Hb, RBC, HCT, iron, and CRP levels. Furthermore, similar to our results, tuberculosis patients with active disease had lower mean values of these variables [28].

 Approximately 65% of the total body iron in circulation in humans is linked to Hb [7], and reduced Hb with chronic infectious diseases is attributable to the limitation of erythropoiesis caused by regulators such as IL-1 and tumor necrosis factor-α [29]. Hb is a source of iron for *Paracoccidioides* spp., which removes iron by hemolytic activity and internalizes protoporphyrin rings through receptor-mediated pathways [30]. Other fungi are also capable of removing iron from Hb, such as *Candida albicans*, through a similar mechanism [31].

 During infection, competition between the pathogen and host for iron uptake involves strategic mechanisms. Therefore, in response to infection, human organisms activate the immune system, thus inducing changes in circulating iron and leading to iron storage in macrophages and decreased absorption of iron from the diet by enterocytes [32]. Furthermore, several inflammatory cytokines are released by immune system cells, and they contribute to alterations in iron metabolism [33]. Despite the host-generated deprivation of iron, all fungi, including *Paracoccidioides* spp., have specific mechanisms for iron uptake through the production of molecules with high affinity for iron, siderophores, iron uptake pathways through reductive iron assimilation, or even Hb receptors [9, 34, 35]. Therefore, an inflammatory response associated with infection alters the availability of circulating iron, thus increasing its intracellular storage and leading to hypoferremia and iron-restricted erythropoiesis, as observed during our study, because these changes can contribute to anemia of inflammation [36].

 The sTfR level is a good indicator of the iron status in the absence of systemic influences; therefore, we analyzed sTfR levels before treatment and at the time of clinical cure. Our results showed that the median values before treatment were normal and did not decrease after treatment, suggesting that the body iron is normal; however, it is distributed

 from functional iron to storage iron. A high sTfR level can indicate iron deficiency [37, 38]. During the storage iron reduction phase, the sTfR level does not change. However, when there is a decrease in functional iron, the synthesis of the transferrin receptor is stimulated; consequently, the sTfR level increases. This parameter is mainly recommended for differentiating iron deficiency anemia from inflammation anemia/chronic disease anemia because the value is increased with iron deficiency anemia but normal with inflammation anemia [39-41]. Studies of pulmonary tuberculosis patients suggested that high sTfR levels in patients with anemia indicate probable iron deficiency and recommended that the sTfR concentration of patients with anemia and an infectious/inflammatory process should be examined [28].

 Another good indicator of iron deficiency with differential anemia is the sTfR/log ferritin ratio [42]. During our study, the sTfR/log ferritin ratio as well as sTfR level were normal before treatment and did not significantly change after treatment, reinforcing the belief that anemia with chronic PCM is inflammation anemia.

 This study presents some limitations. The number of patients is apparently low. However, our Service receives about 15 new cases every year and most of the patients do not undergo the follow-up after clinical improvement, becoming difficult the pairing of some variables – before treatment and after clinical cure.

 In conclusion, PCM interferes with iron metabolism by shifting functional iron to storage iron, as revealed by anemia and low iron levels, with normal TSAT and sTfR levels, normal TIBC, and normal sTfR/log ferritin ratio. Normal or slightly increased ferritin levels, which are characteristic of inflammatory anemia, were observed. However, it should be noted that a few patients had iron deficiency anemia. Therefore, a careful investigation of the iron parameters is important to the clinical management of PCM.

References

- 1. Coutinho ZF, Silva D da, Lazéra M, Petri V, Oliveira RM de, Sabroza PC, et al.
- [Paracoccidioidomycosis mortality in Brazil (1980-1995)]. Cad Saúde Pública.
- 2002;18(5):1441–54.
- 2. Mendes RP, Cavalcante R de S, Marques SA, Marques MEA, Venturini J, Sylvestre TF,
- et al. Paracoccidioidomycosis: Current Perspectives from Brazil. TOMicroJ.
- 2017;11(1):224–82.
- 3. Benard G. Pathogenesis and Classification of Paracocidioidomycosis: New Insights From
- Old Good Stuff. Open Forum Infect Dis. 2021;8(3):624.
- 4. Bailão EFLC, Lima P de S, Silva-Bailão MG, Bailão AM, Fernandes G da R, Kosman
- DJ, et al. *Paracoccidioides* spp. ferrous and ferric iron assimilation pathways. Front
- Microbiol. 2015;6. doi: 10.3389/fmicb.2015.00821.
- 5. DuBois S, Kearney DJ. Iron-Deficiency Anemia and Helicobacter pylori Infection: A
- Review of the Evidence. Am J Gastroenterology. 2005;100(2):453–9.
- 6. Zhang C. Essential functions of iron-requiring proteins in DNA replication, repair and cell
- cycle control. Protein Cell. 2014;5:750–760. doi:10.1007/s13238-014-0083-7.
- 411 7. Gupta C P. Role of iron (Fe) in body. IOSR Journal of Applied Chemistry. 2014;7(11): 38-46.
- 8. Appelberg R. Macrophage nutriprive antimicrobial mechanisms. J Leukoc Biol. 2006;79(6):1117–28.
- 9. Silva-Bailão MG, Bailão EFLC, Lechner BE, Gauthier GM, Lindner H, Bailão AM, et al.
- Hydroxamate Production as a High Affinity Iron Acquisition Mechanism in

- *Paracoccidioides* spp. Roop RM, organizador. PLoS ONE. 2014;9(8):e105805.
- 10. Ozaki KS, Munhoz Júnior S, Pinheiro EK, Tadano T, Fontes CJF. [The diagnosis of
- severe disseminated paracoccidioidomycosis in a bone marrow aspirate: a case report]. Rev
- Soc Bras Med Trop. 1996;29(4):363–6.
- 11. Wians FH, Urban JE, Keffer JH, Kroft SH. Discriminating Between Iron Deficiency
- Anemia and Anemia of Chronic Disease Using Traditional Indices of Iron Status vs
- Transferrin Receptor Concentration. Am J Clin Pathol. 2001;115(1):112–8.
- 12. Cook JD. Clinical evaluation of iron deficiency. Semin Hematol. 1982;19(1):6–18.
- 13. Cook J. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin
- Haematol. 2005;18(2):319–32.
- 14. de Oliveira Custódio JM, Enokida IM, Gonçalves DA, Leone de Oliveira SM do V,
- Venturini J, Carvalho LR, et al. Dynamics of plasma micronutrient concentrations and their
- correlation with serum proteins and thyroid hormones in patients with
- paracoccidioidomycosis. Vicente CR, organizador. PLoS ONE. 2019;14(12):e0226609.
- 15. The jamovi project. Jamovi. 2021. Available in: https://www.jamovi.org.
- 16. Nevitt T. War-Fe-re: iron at the core of fungal virulence and host immunity. Biometals. 2011;24(3):547–58.
- 17. Parente AFA, Bailão AM, Borges CL, Parente JA, Magalhães AD, Ricart CAO, et al.
- Proteomic analysis reveals that iron availability alters the metabolic status of the pathogenic
- fungus *Paracoccidioides brasiliensis*. PLoS One. 2011;6(7):e22810.
- 18. Fabris LR, Andrade ÚV, Santos AFD, Marques AP da C, Oliveira SM do VL de, Mendes
- RP, et al. Decreasing prevalence of the acute/subacute clinical form of
- paracoccidioidomycosis in Mato Grosso do Sul State, Brazil. Rev Inst Med trop S Paulo.

2014;56(2):121–5.

- 19. Queiroz-Telles F, Escuissato DL. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med. 2011;32(6):764–74.
- 20. Matos WB de, Santos GMC dos, Silva VEB da, Gonçalves E da G do R, Silva AR da.
- Paracoccidioidomycosis in the state of Maranhão, Brazil: geographical and clinical aspects.
- Rev Soc Bras Med Trop. 2012;45(3):385–9.
- 21. Peçanha PM, Batista Ferreira ME, Massaroni Peçanha MA, Schmidt EB, Lamas de
- Araújo M, Zanotti RL, et al. Paracoccidioidomycosis: Epidemiological and Clinical Aspects
- in 546 Cases Studied in the State of Espírito Santo, Brazil. Am J Trop Med Hyg.
- 2017;97(3):836–44.
- 22. dos Santos WA, da Silva BM, Passos ED, Zandonade E, Falqueto A. [Association
- between smoking and paracoccidioidomycosis: a case-control study in the State of Espírito
- Santo, Brazil]. Cad Saude Publica. 2003;19(1):245–53.
- 23. Cook JD, Baynes RD, Skikne BS. Iron deficiency and the measurement of iron status.
- Nutr Res Rev. 1992;5(1):198–202.
- 24. Baynes RD. Assessment of iron status. Clinical Biochemistry. 1996; 29 (3): 209–15.
- 25. Leal AMO, Magalhães PKR, Martinez R, Moreira AC. Adrenocortical hormones and
- interleukin patterns in paracoccidioidomycosis. J Infect Dis. 2003;187(1):124–7.
- 26. Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the
- hepcidin era. Haematologica. 2020;105(2):260–72.
- 27. Martinez R, Fiorillo AM. [Effect of treatment of South American blastomycosis
- (paracoccidioidomycosis) on parameters of iron metabolism]. Rev Inst Med Trop Sao Paulo.
- 1978;20(4):190–4.
- 28. Ratnaningsih T, Sukirto NW, Wahyuningsih AT. Soluble Transferrin Receptor (sTfR)
- Identifies Iron Deficiency Anemia (IDA) in Pulmonary Tuberculosis Patients. Acta Med

- Indones. 2020;52(4):334–43.
- 29. Means RT. Advances in the anemia of chronic disease. Int J Hematol. 1999;70(1):7–12.
- 30. Bailão EFLC, Parente JA, Pigosso LL, Castro KP de, Fonseca FL, Silva-Bailão MG, et
- al. Hemoglobin Uptake by *Paracoccidioides* spp. Is Receptor-Mediated. Vinetz JM,
- organizador. PLoS Negl Trop Dis. 2014;8(5):e2856.
- 31. Kuznets G, Vigonsky E, Weissman Z, Lalli D, Gildor T, Kauffman SJ, et al. A relay
- network of extracellular heme-binding proteins drives C. albicans iron acquisition from
- hemoglobin. PLoS Pathog. 2014;10(10):e1004407.
- 32. Muckenthaler MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism.
- Cell. 2017;168(3):344–61.
- 33. Symeonidis AS. The role of iron and iron chelators in zygomycosis. Clin Microbiol
- Infect. 2009;15 Suppl 5:26–32.
- 34. Stanford FA, Voigt K. Iron Assimilation during Emerging Infections Caused by
- Opportunistic Fungi with emphasis on Mucorales and the Development of Antifungal Resistance. Genes (Basel). 2020;11(11):e1296.
- 35. Misslinger M, Hortschansky P, Brakhage AA, Haas H. Fungal iron homeostasis with a
- focus on Aspergillus fumigatus. Biochim Biophys Acta Mol Cell Res. 2021;1868(1):118885.
- 36. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50.
- 37. Baillie FJ, Morrison AE, Fergus I. Soluble transferrin receptor: a discriminating assay for
- iron deficiency. Clin Lab Haematol. 2003;25(6):353–7.
- 38. Punnonen K, Irjala K, Rajamäki A. Iron-deficiency anemia is associated with high
- concentrations of transferrin receptor in serum. Clin Chem. 1994;40(5):774–6.
- 39. Worwood M. Serum transferrin receptor assays and their application. Ann Clin Biochem.
- 2002;39(3):221–30.

- 40. Peng YY, Uprichard J. Ferritin and iron studies in anaemia and chronic disease. Ann Clin Biochem. 2017;54(1):43–8.
- 41. Infusino I, Braga F, Dolci A, Panteghini M. Soluble transferrin receptor (sTfR) and
- sTfR/log ferritin index for the diagnosis of iron-deficiency anemia. A meta-analysis. Am J
- Clin Pathol. 2012;138(5):642–9.
- 42. Skikne BS, Punnonen K, Caldron PH, Bennett MT, Rehu M, Gasior GH, et al. Improved
- differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective
- multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index. Am J
- Hematol. 2011;86(11):923–7.
-

Supporting information

- **S1 Dataset. Dataset containing variables of the study.**
-

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Chronic PCM patients, $n = 88$

Enrolled PCM patients, $n = 39$

a) TIBC

150

d) HCT

Iron ϵ)

